Brief: Sellas Life Sciences Reports Positive Data In Completed Phase 1 Study Of Galinpepimut-S Combined With Opdivo® In Advanced Malignant Pleural Mesothelioma
28/06/2023 14:04
June 28 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES REPORTS POSITIVE DATA IN COMPLETED
PHASE 1
STUDY OF GALINPEPIMUT-S COMBINED WITH OPDIVO® IN ADVANCED
MALIGNANT PLEURAL MESOTHELIOMA
* SELLAS LIFE SCIENCES GROUP INC - PRIMARY ENDPOINT OF
SAFETY AND
EFFICACY ENDPOINT BOTH MET WITH CLINICAL ACTIVITY AND INCREASED
SURVIVAL OBSERVED
* SELLAS LIFE SCIENCES GROUP INC - NO DOSE LIMITING
TOXICITIES
OBSERVED
* SELLAS LIFE SCIENCES GROUP INC - ADDITIONAL IMMUNE
RESPONSE DATA
FROM ALL TEN PATIENTS IS EXPECTED BY Q4 2023
Source text for Eikon: ID:nGNXc2wwVk
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses